Pheochromocytomas are rare catecholamine-producing tumors derived in more than 30% of cases from mutations in 9 tumorsusceptibility genes identified to date. Testing of multiple genes is often undertaken at considerable expense before a mutation is detected. This study assessed whether measurements of plasma metanephrine, normetanephrine, and methoxytyramine, the O-methylated metabolites of catecholamines, might help to distinguish different hereditary forms of the tumor.
.
Reported frequencies of germline mutations of the above genes among patients with PPGLs range from 27% to 32% (3) (4) (5) . This frequency is likely to increase as further tumor susceptibility genes are identified. Most recently mutations of genes encoding the SDH complex assembly factor 2 (SCHAF2), transmembrane protein 127 (TMEM127), and SDH subunit A (SDHA) have been identified as further hereditary causes of PPGLs (6 -8 ) . This brings together a total of 9 tumor susceptibility genes now recognized as responsible for hereditary PPGLs.
Findings that substantial proportions of germline mutations of tumor susceptibility genes occur in patients without a syndromic presentation or obvious hereditary basis for the tumors provide an argument for genetic testing of all patients with PPGLs (4, 9 ) . It is nevertheless widely recommended that it is neither appropriate nor cost-effective to test every diseasecausing gene in all patients with PPGLs; rather the decision to test and which genes to test requires judicious consideration of numerous factors (10 -12 ) . The catecholamine biochemical phenotype of tumors has been suggested as a factor that is potentially useful in guiding decision-making (3, 12 ) . However, available data to support this link remain limited, and differences in biochemical phenotypes are usually not considered in algorithms for genetic testing (11, 13, 14 ) .
Although PPGLs in MEN 2 and VHL patients show striking differences in tumor contents, metabolism, and secretion of norepinephrine and epinephrine (15) (16) (17) , it is not yet clear whether other hereditary PPGLs are also characterized by similarly distinct differences. There is some evidence that tumors in patients with SDHB mutations are characterized by norepinephrine and dopamine production (18 ) , but that evidence is based largely on measurements of the plasma catecholamines. Such data derived during diagnostic testing are more readily available than those derived from tumor tissue, and are therefore more accessible to guide genetic testing. Nevertheless, in any study in which investigators are seeking to characterize the catecholamine phenotypes of PPGLs, they should also establish that any neurochemical differences indicated by diagnostic tests do in fact reflect underlying differences in the tumors themselves. Also, in any study in which diagnostic data are used to examine catecholamine phenotypes, the most sensitive diagnostic tests available should be used.
Because PPGLs do not always secrete catecholamines, measurements of these analytes in plasma and urine often fail to reveal the presence of the tumors (19 ) . In contrast, PPGLs continuously metabolize catecholamines to the O-methylated metabolites by a process that is independent of variations in catecholamine release (20 ) . Thus, measurements of plasma free normetanephrine and metanephrine, the respective O-methylated metabolites of norepinephrine and epinephrine, represent the most sensitive tests to diagnose catecholamine production by PPGLs (19 ) . Additional measurements of methoxytyramine, the O-methylated metabolite of dopamine, provide a further useful analyte for indicating tumor production of dopamine (21 ) , but as yet have not been established to show differences among various hereditary groups of PPGLs.
In the present analysis we used a data set from a large population of patients with hereditary PPGLs, linked to a tumor tissue bank, to examine whether the 5 main hereditary forms of PPGLs might be distinguished by differences in plasma concentrations of the O-methylated metabolites. The aim was not to determine whether such information derived from diagnostic testing could be used to distinguish patients with hereditary from sporadic disease, but rather to establish whether diagnostic test results might offer utility to guide selection of genes for testing among patients with PPGLs and no clinical evidence of a particular hereditary syndrome.
Materials and Methods

PATIENTS
The study involved retrospective analysis of data from 173 patients with hereditary PPGLs. We investigated 151 individuals for whom data were available at NIH (Bethesda, Maryland) and 22 at European centers, including Radboud University Medical Center (Nijmegen the Netherlands), the University of Florence (Florence, Italy), and Dresden University Hospital (Dresden, Germany). Written informed consent, which also allowed for collection of specimens and data at off-site centers, was obtained from patients enrolled in intramural review-board-approved studies at NIH. At European centers, when informed consent was not obtained, the data were collected under conditions of regular clinical care, with ethical committee approval obtained for the use of those data.
Among the 173 patients with hereditary PPGLs, there were 66 with VHL syndrome, 38 with MEN 2, 10 with NF1, 48 with mutations of the SDHB gene, and 11 with mutations of the SDHD gene. Mutations were confirmed by genetic testing in all patients with MEN 2, VHL syndrome, and hereditary PPGLs due to mutations of SDHD and SDHB genes. Diagnosis of NF1 was based on clinical criteria.
COLLECTIONS OF BLOOD, URINE, AND SURGICAL SPECIMENS
Blood samples from all patients were obtained after each individual had been in a supine position for at least 20 min. Participants were instructed to fast and abstain from caffeinated and decaffeinated beverages overnight and avoid taking acetaminophen for 5 days before blood sampling. Samples of blood were transferred into tubes containing heparin as an anticoagulant and immediately placed on ice until centrifuged (4°C) to separate the plasma. Plasma samples were stored at Ϫ80°C until assayed. We collected 24-hour urine samples from 162 patients and used hydrochloric acid as a preservative. Total urine volume was determined and aliquots were stored at 4°C until assayed.
Samples of tumor tissue were procured from 90 patients. Small samples of each tumor (10 -50 mg) were dissected from the mass, frozen on dry ice, and stored at Ϫ80°C. For further processing, tissue samples were weighed frozen and then homogenized in at least 5 volumes of 0.4 mol/L perchloric acid containing 0.5 mmol/L EDTA. Homogenized samples were centrifuged (1500g for 15 min at 4°C) and supernatants collected and stored at Ϫ80°C until assayed for catecholamines.
LABORATORY ANALYSES
Plasma concentrations of free metanephrine, normetanephrine, and methoxytyramine were quantified by liquid chromatography with electrochemical detection as described previously (21, 22 ) . Intraassay CVs, established from an interlaboratory quality assurance program described by Pillai and Callen (23 ) , varied over cycles of assessment between 2.2%-7.1% for metanephrine, 5.9%-8.7% for normetanephrine, and 8.0%-23.9% for methoxytyramine.
Concentrations of catecholamines (epinephrine, norepinephrine and dopamine) in plasma and tumor tissue were also quantified by liquid chromatography with electrochemical detection (24, 25 ) . Twenty-fourhour urinary outputs of catecholamines (epinephrine, norepinephrine and dopamine) and deconjugated (free plus conjugated) fractionated metanephrines (metanephrine and normetanephrine) were measured at outside laboratories by HPLC or by liquid chromatography with tandem mass spectroscopy as described previously (26 ) .
Reference intervals for plasma concentrations of metanephrine (0.06 -0.31 nmol/L), normetanephrine (0.10 -0.61 nmol/L), methoxytyramine (0.006 -0.090 nmol/L), epinephrine (0.02-0.45 nmol/L), norepinephrine (0.47-2.95 nmol/L), and dopamine (0.013-0.379 nmol/L) were established from combined groups of 175 normotensive and 110 hypertensive volunteers, as described previously (21 ) . Reference intervals for 24-h urinary outputs of metanephrine (0.22-1.32 mol/24 h), normetanephrine (0.70 -2.64 mol/24 h), free epinephrine (0 -0.11 mol/24 h), free norepinephrine (0.09 -0.47 mol/24 h), and free dopamine (0.39 -2.63 mol/24 h) were those provided by the outside laboratories responsible for the measurements.
STATISTICS
We assessed differences between multiple groups by 1-way ANOVA. Post hoc tests used the Tukey-Kramer test. Linear discriminant analysis was carried out to determine which combinations of biomarkers optimally classified patients according to their hereditary condition. This analysis was performed with stepwise variable selection using the JMP statistics software package (SAS Institute). Principal components analysis was used to select combinations of the 3 most appropriate biomarkers that clustered data in n-dimensional space separately according to hereditary condition. Data underwent a logarithmic transformation before multivariate analyses.
Results
TUMOR LOCATIONS AND TISSUE CATECHOLAMINES
Tumor locations and presence of metastases varied considerably among patients with different hereditary conditions ( Table 1) . Tumors in patients with VHL syndrome, MEN 2, and NF1 were mainly confined to the adrenal glands (Ͼ88%). Eight patients with VHL syndrome had extraadrenal tumors, including 3 with combined adrenal and extraadrenal tumors. Among the patients with MEN 2 and NF1 there was 1 isolated NF1 patient with a single aortic retroperitoneal tumor; all others had adrenal tumors. In contrast, 90% of patients with SDHB mutations and 46% of patients with SDHD mutations had tumors with exclusively extraadrenal locations; the other patients had either solitary adrenal tumors or combined adrenal and extraadrenal tumors. Patients with SDHB mutations were characterized by a higher rate of malignancy compared to patients in other groups.
Tumor tissue contents of catecholamines varied considerably among the different groups of patients with PPGLs (Fig. 1) . The presence of markedly higher tumor tissue contents of epinephrine in patients with MEN 2 and NF1 than in those with mutations of VHL, SDHB, and SDHD genes represented the clearest distinguishing feature. In patients with VHL, SDHB, and SDHD gene mutations, tumor tissue contents of epinephrine averaged Ͻ2% of the total combined con-tents of all catecholamines, whereas in patients with MEN 2 and NF1, epinephrine represented on average 50% and 43% of total tumor catecholamine contents, respectively. Tumor tissue concentrations of dopamine were generally a minor component of tissue catecholamines, representing Ͻ1% of the total contents of catecholamines in all groups of patients except those with SDHB mutations. Tissue dopamine concentrations in tumors from these patients represented on average 26% of the total contents of all catecholamines, but showed considerable variation, ranging from Ͻ1% to 95% of the total.
Tumor contents of epinephrine expressed as a percent of total catecholamine contents were positively correlated with increases in plasma metanephrine expressed as a percent of increases in the summed total of all O-methylated metabolites (r ϭ 0.920, P Ͻ 0.001). Similarly, percent tumor tissue contents of dopamine were positively correlated with increases in plasma methoxytyramine expressed as a percent of increases of all O-methylated metabolites (r ϭ 0.922, P Ͻ 0.001).
PLASMA AND URINARY NORMETANEPHRINE AND
NOREPINEPHRINE
Considered alone, plasma concentrations of normetanephrine and norepinephrine showed no obvious distinguishing differences among the 5 groups of patients with hereditary PPGLs (Fig. 2,A and B) . Nevertheless, measurements of plasma normetanephrine were distinctly superior to those of norepinephrine for indicating tumoral norepinephrine production. More specifically, plasma concentrations of norepinephrine were below the upper limits of the population reference interval in 54 of the 173 patients with hereditary PPGLs (31%) compared to only 17 patients (10%) for plasma normetanephrine. Similarly urinary outputs of norepinephrine were within reference intervals in 34% of patients compared to only 14% of patients with urinary outputs of normetanephrine that were within reference intervals (Table 2) .
PLASMA AND URINARY METANEPHRINE AND EPINEPHRINE
In contrast to the general lack of distinguishing differences for plasma normetanephrine among the 5 patient groups ( Fig. 2A) , plasma concentrations of metanephrine almost completely distinguished patients with MEN 2 and NF1 from those with mutations of VHL, SDHD, and SDHB genes (Fig. 2C) . More specifically, plasma concentrations of metanephrine were strongly increased in patients with MEN 2 and NF1, but mostly below the upper limits of the reference interval in patients with VHL, SDHD, and SDHB mutations. Among the 125 latter patients, 12 (10%) had increases in plasma metanephrine above the upper limits of the reference interval, resulting in some overlap with concentrations in MEN 2 and NF1 patients.
Plasma concentrations of metanephrine were clearly superior to epinephrine (Fig. 2, C and D) for indicating tumoral epinephrine production and distinguishing patient groups according to underlying mutations. Of note, whereas plasma concentrations of 
Presence of metastases 5 (8%) 2 (5%) 0 (0%) 41 (85%) 4 (36%)
metanephrine were increased in all patients (100%) with MEN 2 or NF1, plasma concentrations of epinephrine were increased above reference intervals in only 24 (51%) of these patients.
Urinary outputs of metanephrine were similarly more effective than outputs of epinephrine for indicating the presence of epinephrine-producing tumors in NF1 and MEN 2 patients (Table 2) ; 97% of patients in these 2 groups had increased urinary metanephrine compared to 62% with increased epinephrine.
Among the patients with NF1 and MEN 2, there was 1 NF1 patient with an extraadrenal tumor located in the retroperitoneum. Plasma concentrations and urinary outputs of metanephrine (1.74 nmol/L and 7.78 mol/day) were, nevertheless, well above the upper limits of the reference intervals for both analytes (0.31 nmol/L and 1.32 mol/day). Among the patients with mutations in the genes encoding SDH, there were 11 who had tumors with adrenal locations. Plasma and urinary concentrations of metanephrine were below the upper limits of the reference interval in all except 2 of these patients. For 1 patient, plasma metanephrine was slightly increased at 0.37 nmol/L. That patient, however, had an increase in plasma normetanephrine (8.08 nmol/L) well above the upper limit of the reference interval (0.61 nmol/L) and no increase in urinary metanephrine (0.05 mol/day) indicating relatively little if any tumoral epinephrine production. The second patient had a slightly increased urinary output of metanephrine (1.84 mol/day), a dramatically increased urinary output of normetanephrine (132 nmol/day), and a plasma concentration of metanephrine within reference intervals (0.05 nmol/L), again indicating negligible tumoral epinephrine production.
PLASMA METHOXYTYRAMINE AND DOPAMINE
Plasma concentrations of methoxytyramine and dopamine showed additional patterns useful for distinguishing patients with SDH gene mutations from those with other hereditary syndromes (Fig. 2, E and F) . More specifically, 72% of patients with SDHB mutations and 67% with SDHD mutations had increases of plasma free methoxytyramine, compared to 17% for patients with VHL mutations and 39% for patients with NF1 or MEN 2. Similarly, 42% of patients with mutations of SDHD or SDHB genes had elevations of plasma dopamine compared to 5% of patients with VHL syndrome, MEN 2, and NF1. Urinary outputs of dopamine were also increased in 40% of patients with mutations of SDHD and SDHB genes, compared to 13% of patients with other gene mutations ( Table 2) .
BIOMARKER COMBINATIONS
The 10% of patients with VHL, SDHB, or SDHD mutations who exhibited slight increases of metanephrine above the upper reference intervals (Fig. 2C ) also generally had large increases in plasma normetanephrine so that proportional increases in metanephrine were minimal. Combinations of biomarkers were therefore considered for distinguishing the various groups of patients.
Discriminant analysis indicated that measurements of plasma metanephrine considered alone could be used to correctly classify 97% of patients into 2 groups: 1 group with MEN 2 and NF1 and the other with mutations of VHL and genes encoding SDH (Table 3). Measurements of normetanephrine and methoxytyramine used alone or in combination offered no discriminatory information for this classification. However, when either or both of these measurements were combined with measurements of plasma metanephrine there was further improvement, with more than 99% of cases correctly classified. Measurements of plasma and urinary catecholamines were less effective than plasma metanephrines for correctly classifying patients into the 2 groups, whereas measurements of urinary metanephrine exhibited similar effectiveness to measurements of plasma metanephrine.
Measurements of plasma methoxytyramine provided the best single biomarker for further distinguishing VHL patients from patients with mutations of SDHB and SDHD genes, correctly classifying 78% patients into either of these 2 groups (Table 3) . Discriminant scores were negligibly increased by further combinations of biomarkers and remained higher than scores achieved for tests of plasma or urinary dopamine in combination with other biomarkers.
As illustrated by 3-dimensional plots of plasma concentrations of normetanephrine, metanephrine and methoxytyramine, data from patients with MEN 2 and NF1 clustered together within a group distinct from patients with mutations of VHL and SDH genes (Fig. 3) . Data from patients with VHL and SDH gene mutations also showed 2 separate but overlapping clusters. For patients with MEN 2 there were strong positive relationships for plasma concentrations of normetanephrine vs metanephrine (r ϭ 0.640, P Ͻ 0.001), normetanephrine vs methoxytyramine (r ϭ 0.618, P Ͻ 0.001), and metanephrine vs methoxytyramine (r ϭ 0.551, P Ͻ 0.001). In contrast, for patients with VHL or SDH gene mutations, plasma concentrations of metanephrine showed no relationships with either of the 2 other biomarkers; positive relationships were observed only for plasma concentrations of normetanephrine vs methoxytyramine (VHL, r ϭ 0.577, P Ͻ 0.001; and SDH genes, r ϭ 0.318, P ϭ 0.017).
Discussion
This study establishes that measurements of the O-methylated metabolites of catecholamines, in addition to providing useful diagnostic biomarkers for PPGLs, also enable discrimination of different hereditary forms of these tumors. Findings of distinct profiles for catecholamine O-methylated metabolites among different groups of patients with hereditary tumors are supported by additional measurements of catecholamines in tumor tissue and novel data are presented showing that plasma methoxytyramine provides a particularly sensitive biomarker for indicating tumoral dopamine production in patients with mutations of SDHB and SDHD genes.
Increased plasma concentrations of metanephrine due to pheochromocytomas in patients with MEN 2 and normal concentrations in VHL syndrome are established findings (15, 27 ) , but it has not been clear whether other hereditary PPGLs are characterized by similarly distinct differences. As now shown here, tumors in patients with NF1 share a similar adrenergic phenotype to those in patients with MEN 2. Both groups develop tumors containing considerable epinephrine leading to consistently increased plasma concentrations of metanephrine, but with increases in plasma and urinary epinephrine in less than two-thirds of cases. In contrast to MEN 2 and NF1 groups, tumors from patients with VHL, SDHD, and SDHB mutations are characterized by low tissue levels of epinephrine with corresponding, usually within reference intervals, concentrations of metanephrine and epinephrine in plasma and urine. When plasma concentrations of metanephrine are increased, the increases are minor compared to the proportionally much larger increases of normetanephrine. Discriminant analysis revealed that by additional consideration of normetanephrine and methoxtyramine, measurements of plasma metanephrine enable virtually all patients with mutations of VHL and SDH genes to be distinguished from those with MEN 2 and NF1.
There is some evidence that tumors in patients with SDHB mutations are characterized by predominantly norepinephrine production, which in some patients includes additional increases in plasma dopamine (18 ) . That evidence, however, did not include measurements of plasma methoxytyramine or tumor tissue dopamine. The present study reports for the first time that more than two-thirds of patients with either SDHB or SDHD mutations have increases in plasma methoxytyramine and that in the former patients this finding reflects the tumor contents of dopamine. Consistent with these observations, plasma concentrations and urinary outputs of dopamine were also more often increased in patients with PPGLs due to SDH gene mutations than in other groups. Results of discriminant analysis indicated, however, that measurements of plasma and urinary dopamine are less useful than measurements of plasma methoxytyramine for distinguishing patients with PPGLs due to SDH gene mutations from other groups.
Routine testing of tumor susceptibility genes is now often carried out in patients with PPGLs even when there is no evidence of a familial syndrome, a result of findings that up to 24% of such patients harbor unsuspected germ-line mutations of these genes (4, 9, 28 ) . Such testing is extremely expensive. Considerable effort is therefore being expended in establishing guidelines and algorithms for cost-effective genotyping of patients with PPGLs (5, 10 -14, 29 -32 ) .
Early age of presentation of tumors provides a commonly used justification for genetic testing. Beyond this and in the absence of suggestive clinical stigmata, the locations of tumors and presence of malignancy provide important clues about which genes should be first tested (4, 5, 10, 30, 33 ) . Extraadrenal tumor location, particularly when multifocal, justifies testing of SDH genes. Presence of malignancy mandates testing of the SDHB gene. More recently, immunohistochemical analysis of SDH subunit B (SDHB) expression in resected tumor specimens has been advocated as a useful method to stratify patients with and without SDH gene mutations, and thereby guide costeffective genetic testing (34, 35 ) .
The data here indicate another approach to streamline targeted testing of underlying germline mutations based on readily available and easily used results of inexpensive biochemical tests used during diagnosis of PPGLs. For patients in whom there are no characteristic clinical stigmata or family history to guide genetic testing, patterns of increases in plasma normetanephrine, metanephrine, and methoxytyramine should provide useful information to determine the most appropriate genes to test. Testing of the RET gene appears warranted only for patients with tumors characterized by increases of plasma metanephrine. In patients with solitary increases of plasma normetanephrine, mutations of VHL, SDHD, and SDHB genes remain possible. Among these patients, further stratification for genotyping should be possible from measurements of plasma methoxytyramine. For those patients found to have tumors that produce increases of plasma methoxytramine, with or without additional increases of normetanephrine, testing of SDHB and SDHD genes appears warranted. In patients with solitary increases of normetanephrine, additional testing of the VHL gene may be considered.
Combined with consideration of other factorssuch as tumor location, metastatic involvement, and immunohistochemistry studies of tumor tissue SDHB expression-the data derived from diagnostic testing should offer a useful approach to select genes for testing. Validation of such utility, however, requires additional well-considered prospective studies directed at patients without a familial or syndromic presentation in whom factors already proposed for stratification of patients for gene testing may also be used. From this it should be possible to establish formal cut-offs for ages, catecholamine phenotypes and other indices beyond which testing for specific genes is not clinically indicated.
In addition to providing information for gene testing, the results of this study have other immediate implications for patient care. In patients with confirmed mutations of SDHB or SDHD genes who must undergo periodic surveillance for PPGLs, our data indicate that the effectiveness of biochemical screening may be enhanced by additional measurements of plasma methoxytyramine and dopamine. This can be expected to be particularly important for detecting the occasional patients with tumors producing dopamine exclusively or near exclusively (21 ) . Similarly during screening for PPGLs in patients with MEN 2 or NF1, interpretation of biochemical test results should be focused on measurements of both metanephrine and normetanephrine. In contrast, in VHL syndrome the focus should be on normetanephrine.
In summary, the present study establishes distinct profiles of plasma concentrations of normetanephrine, metanephrine, and methoxytyramine among different groups of patients with hereditary PPGLs. Measurements of these biomarkers provide information that should be useful for guiding efficient and cost-effective genotyping. The distinct profiles are also important to consider during periodic testing for PPGLs in patients who are at risk for the tumors because of underlying germline mutations of tumor susceptibility genes.
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